C3-targeted Therapy in Periodontal Disease: Moving Closer to the Clinic
George Hajishengallis,Hatice Hastürk,John D. Lambris,Danae A. Apatzidou,Georgios N. Belibasakis,Nagihan Bostancı,Patricia Corby,Christopher W. Cutler,Francesco D’Aiuto,Evlambia Hajishengallis,Markus Huber‐Lang,Effie Ioannidou,Tetsuhiro Kajikawa,Alpdoğan Kantarcı,Jonathan Korostoff,Georgios A. Kotsakis,Tomoki Maekawa,Dimitrios C. Mastellos,Niki M. Moutsopoulos,Srinivas R. Myneni,Richard H Nagelberg,Bo Nilsson,Panos N. Papapanou,Evgenia Papathanasiou,Jan Potempa,Antonio M. Risitano,Sinem E. Sahingur,Atsushi Saitô,Anton Sculean,Andreas Stavropoulos,Flavia Teles,Maurizio S. Tonetti,Despina Yancopoulou
DOI: https://doi.org/10.1016/j.it.2021.08.001
IF: 19.709
2021-01-01
Trends in Immunology
Abstract:Complement plays a key role in immunosurveillance and homeostasis. When dysregulated or overactivated, complement can become a pathological effector, as seen in several inflammatory disorders, including periodontal disease. Recently, clinical correlative studies and preclinical mechanistic investigations have collectively demonstrated that complement is hyperactivated during periodontitis and that targeting its central component (C3) provides therapeutic benefit in nonhuman primates (NHPs). The preclinical efficacy of a C3-targeted drug candidate combined with excellent safety and pharmacokinetic profiles supported its use in a recent Phase IIa clinical study in which C3 inhibition resolved gingival inflammation in patients with periodontal disease. We posit that C3-targeted intervention might represent a novel and transformative host-modulation therapy meriting further investigation in Phase III clinical trials for the treatment of periodontitis.